HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibition of TNF-alpha-induced RANTES expression in human hepatocyte-derived cells by fibrates, the hypolipidemic drugs.

Abstract
Increased concentrations and activity of plasma cytokines produced by monocytes, macrophages, and hepatocytes in patients with alcoholic liver diseases, correlate with the clinical course of liver diseases and are of prognostic value. Especially, high levels of circulating tumor necrosis factor (TNF)-alpha have been found to correlate with increased mortality in alcoholic hepatitis. Moreover, hepatic RANTES was increased in patients with alcoholic hepatitis. Thus, TNF-alpha-induced RANTES expression may have a critical role in cell-mediated liver injury associated with alcoholic hepatitis. Fibrates are widely used in the treatment of hyperlipidemia and lower triglyceride levels in patients with hyperlipidemia. Recently, several groups reported that bezafibrate, one of fibrates, is effective in primary biliary cirrhosis treatment. Additionally, it is reported that bezafibrate is effective in the treatment not only of primary biliary cirrhosis but also of chronic hepatitis C and tamoxifen-induced non-alcoholic steatohepatitis. We, here, presented that bezafibrate and fenofibrate repressed TNF-alpha-induced protein production and mRNA expression of RANTES in human hepatocyte-derived cells. Luciferase assay showed that bezafibrate and fenofibrate inhibited RANTES gene expression in response to TNF-alpha. Moreover, bezafibrate repressed TNF-alpha-induced DNA-binding activity of NF-kappaB. Thus, fibrates reduced TNF-alpha-induced NF-kappaB activation and RANTES expression, possibly suggesting that fibrates might be inhibitory agents of migration of inflammatory cells by RANTES to the liver in patients with alcoholic liver diseases. In line of these results, it might be possible that fibrates are therapeutic agents in alcoholic liver diseases.
AuthorsFuminori Hirano, Atsushi Kobayashi, Isao Makino
JournalInternational immunopharmacology (Int Immunopharmacol) Vol. 3 Issue 2 Pg. 225-32 (Feb 2003) ISSN: 1567-5769 [Print] Netherlands
PMID12586603 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2003 Elsevier Science B.V.
Chemical References
  • Chemokine CCL5
  • Hypolipidemic Agents
  • RNA, Messenger
  • Tumor Necrosis Factor-alpha
  • DNA
  • Fenofibrate
  • Bezafibrate
Topics
  • Bezafibrate (pharmacology)
  • Chemokine CCL5 (biosynthesis, genetics)
  • DNA (metabolism)
  • Fenofibrate (pharmacology)
  • Gene Expression Regulation (drug effects)
  • Hepatocytes (drug effects, metabolism)
  • Humans
  • Hypolipidemic Agents (pharmacology)
  • RNA, Messenger (analysis)
  • Tumor Cells, Cultured
  • Tumor Necrosis Factor-alpha (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: